As previously discussed, early clinical trials of first generation EGFR TKIs were conducted in molecularly non-selected cohorts of patients with advanced NSCLC (Fukuoka et al., 2003; Shepherd et al., 2005; Thatcher et al., 2005). Here, EGFR is linked to non-small cell lung carcinoma.